- Home
- LPG vs PRTA Comparison
LPG vs PRTA Comparison
Compare LPG & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPG
- PRTA
- Stock Information
- Founded
- LPG 2013
- PRTA 2012
- Country
- LPG United States
- PRTA Ireland
- Employees
- LPG N/A
- PRTA N/A
- Industry
- LPG Marine Transportation
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- LPG Consumer Discretionary
- PRTA Health Care
- Exchange
- LPG Nasdaq
- PRTA Nasdaq
- Market Cap
- LPG 913.3M
- PRTA 809.8M
- IPO Year
- LPG 2014
- PRTA N/A
- Fundamental
- Price
- LPG $22.35
- PRTA $12.38
- Analyst Decision
- LPG Strong Buy
- PRTA Buy
- Analyst Count
- LPG 1
- PRTA 9
- Target Price
- LPG $35.00
- PRTA $54.57
- AVG Volume (30 Days)
- LPG 783.7K
- PRTA 439.8K
- Earning Date
- LPG 05-21-2025
- PRTA 05-07-2025
- Dividend Yield
- LPG 16.56%
- PRTA N/A
- EPS Growth
- LPG N/A
- PRTA N/A
- EPS
- LPG 3.87
- PRTA N/A
- Revenue
- LPG $416,947,918.00
- PRTA $135,157,000.00
- Revenue This Year
- LPG N/A
- PRTA N/A
- Revenue Next Year
- LPG $10.11
- PRTA $131.75
- P/E Ratio
- LPG $5.78
- PRTA N/A
- Revenue Growth
- LPG N/A
- PRTA 47.92
- 52 Week Low
- LPG $19.36
- PRTA $11.70
- 52 Week High
- LPG $51.66
- PRTA $26.36
- Technical
- Relative Strength Index (RSI)
- LPG 49.87
- PRTA 38.08
- Support Level
- LPG $20.00
- PRTA $12.46
- Resistance Level
- LPG $23.85
- PRTA $13.52
- Average True Range (ATR)
- LPG 0.67
- PRTA 0.73
- MACD
- LPG 0.12
- PRTA -0.08
- Stochastic Oscillator
- LPG 58.65
- PRTA 23.24
About LPG Dorian LPG Ltd.
Dorian LPG Ltd is an international liquefied petroleum gas shipping company focused on owning and operating gas carriers, or VLGCs. The company currently owns and operates around 22 modern VLGCs, including nineteen new fuel-efficient 84,000 cbm ECO-design VLGCs. Dorian LPG has offices in Connecticut, USA, London, United Kingdom, and Athens, Greece.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).